PCM
HZNP

Prelude Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Prelude Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-32,600
Closed -$3.77M – 1494
2023
Q3 		$3.77M Sell
32,600
-10,400
-24% -$1.12M 0.25% 87
2023
Q2 		$4.42M Buy
+43,000
New +$4.54M 0.29% 64
2015
Q3 		– Sell
-2,500
Closed -$87K – 1936
2015
Q2 		$87K Buy
+2,500
New +$76.3K 0.01% 933

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's HZNP Position: Q4 2023 in Review

Prelude Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 135,854 shares — an estimated $15.7M sold.

Prelude Capital Management first reported a position in HZNP in Q2 2014 and held it in 21 quarters. The position peaked at $16.6M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Prelude Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Prelude Capital Management sold 135,854 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $15.7M.
  • Prelude Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 21 quarters.
  • Prelude Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $16.6M in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.